KYMR Kymera Therapeutics

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report third quarter 2024 financial results on October 31, 2024, and will host a conference call at 8:30 a.m. ET.

To access the October 31 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of the Company’s conference call will be available under “” in the Investors section of the Company’s website at . A replay of the webcast will be archived and available following the event.

About Kymera Therapeutics

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit or follow us on or .

Investor and Media Contact: 

Justine Koenigsberg

Vice President, Investor Relations





857-285-5300



EN
23/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kymera Therapeutics

 PRESS RELEASE

Kymera Therapeutics to Participate in Upcoming December Investor Confe...

Kymera Therapeutics to Participate in Upcoming December Investor Conferences WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Piper Sandler 36th Annual Healthcare Conference in New York, NY on December 3 at 1:00 p.m. ET; and7th Annual Evercore ISI HealthCONx Conference in Coral Gables, FL on December 4 at 4:15 p.m. ET. Live w...

 PRESS RELEASE

Kymera Therapeutics to Participate in Upcoming November Investor Confe...

Kymera Therapeutics to Participate in Upcoming November Investor Conferences WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA on November 12 at 10:00 a.m. ET;J.P. Morgan Equity Opportunities Forum in Miami, FL on November 14, one-on-one meetings only;Stife...

 PRESS RELEASE

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and...

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to dose ranging Phase 2b studies to accelerate overall development timelines; completion of both expanded trials expected by mid-2026 KT-295, a new TYK2 degrader, selected as the development candidate to advance into Phase 1 clinical trial in the first half of 2025, in line with prior ...

 PRESS RELEASE

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 C...

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases KT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases Phase 1 healthy volunteer data expected to be reported in the first half of 2025 WATERTOWN, Mass., Oct. 24, 202...

 PRESS RELEASE

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on ...

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report third quarter 2024 financial results on October 31, 2024, and will host a conference call at 8:30 a.m. ET. To access the October 31 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch